The Chronicle of Healthcare Marketing - November 2015

Page 1

Inside: Canadian Healthcare Marketing Hall of Fame Commemorative Booklet

OUR ANNUAL REPORT ON MARKETING: Charting the modern evolution of the agency/client relationship • 4 OTSUKA CANADA: GM Allison Rosenthal explains the science behind corporate culture • 5 MY TURN: Local governments contributing to Canada’s $500 million drug problem • 14

$7.95 • November 30, 2015 • Covering Canadian and Global Pharmaceutical Economics • www.pharmacongress.info

Biosimilars market a little murky SEBs

Publications Mail Agreement No. 40016917

n Not considered generics by Health Canada, since it is virtually impossible to make identical product

T

By Ian J.S. Moore

HEALTHCARE MARKETING

HERE IS SOME CONFUSION AROUND

Girls just want to have fun

Pop stylist Cyndi Lauper is heading up an awareness campaign for the National Psoriasis Foundation to highlight the physical, emotional and social challenges of living with the disease. With sponsor Novartis, Lauper aims to inspire people with psoriasis by describing her own experiences. “[Psoriasis] made me want to hide, but being in the public eye I knew I couldn’t stay inside,” she says. (PR NewsFoto/National Psoriasis Foundation)

Pharma industry growth pegged at about 5 per cent annually through 2019 The business of pharma

© MMXV, All rights reserved. Chronicle I/R Ltd.

of THE CHRONICLE OF

n Top 15 brands growing, but none has a market share that escapes single digits

C

By Ian J.S. Moore,

for THE CHRONICLE OF HEALTHCARE MARKETING

ANADIAN PHARMAS’ TOTAL MARKET

purchases will grow to $29.6-billion in the five years between 2015 and 2019—an increase of $5.1-billion— according to forecasts delivered by IMS Brogan prexy Michael Brogan during his annual PharmaFocus 2019 presentation in Toronto. The recorded annual percentage growth is expected to be between 4.9 per cent and 5.3 per cent during this period, he said. Using actual market prices in its forecasts, the company says brand products will lead the way, growing to $23.86 billion in 2019 from $19.23-billion in purchases this year, an impressive gain of $4.63-billion (all figures are in Canadian dollars). Sales of generics will also increase during this period, but by a less impressive

$520 million to $5.81-billion. Brogan said pharmas’ market growth projections are optimistic, as the company’s figures and charts showed the industry is emerging from the gloomy, recessive market growth situations it experienced in recent years. “We expect to remain out of [recessive growth] for the foreseeable future.” he said. Brogan A growth in the sales of Hepatitis C medications, the pan-Canadian Pharmaceutical Alliance, and considerations by both private payers and the federal government of joining the pCPA can be counted among the drivers in this growth forecast. Also taken into consideration is the expected sales growth in subsequent entry biologics (SEBs) and inhaler products.

The list of top 15 brands last year presented a mixed bag of sales and growth increases. While Lucentis, Cymbalta, Humira, Remicade and Coversyl were leaders with double-digit percentage market growths, their market shares were all lower, single-digit numbers.

REMICADE IN LEAD

At 3.4 per cent, Remicade claimed the leadership title in purchase volume by brands last year; none of the other top market growth leaders reached more than the 2.2 per cent recorded by Humira. The “wild card” in 2015, according to Brogan, will be the sales totals achieved in

Turn to Canadian Pharma page 8à

the manufacturing and marketing regs governing biologic biosimilars and subsequent entry biologics, if questions from the floor are any indication. During a presentation at the PharmaFocus 2018 meeting in Montreal, Anne Tomalin, president of Therapeutic Products Inc., a boutique firm in Hamilton that deals with Canadian regulatory affairs, clarified some issues and misconceptions. A biologic, she explained, is a medicine made from living organisms or cells through a complex manufacturing procedure, and the smallest change in this procedure can affect the final product and its effect in the human body. A biosimilar is a copy of a biologic that is similar, but not identical to, an original medicine. BIOSIMILARS NOT IDENTICAL

“Think about a generic small molecule,” she said. “A generic small molecule is the identical amount of the identical ingredient in a similar dosage form for the same indication [and] taken by the same route of administration. “It’s much, much more difficult when you get to a biologic. You really can’t tell that they’re identical anymore.” Health Canada’s defines these products as Subsequent Entry Biologics (SEB), but in Europe and other countries they are generally known as biosimilars. “A subsequent entry biologic [in Canada],” Tomalin said, “is a biologic drug that enters the market subsequent to a version previously authorized in Canada and with demonstrated similar-

Turn to Biosimilars page 10à


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.
The Chronicle of Healthcare Marketing - November 2015 by Chronicle - Issuu